These data indicate that the HER2-HER3 heterodimer plays an important role in brain metastasis, potentially having dire consequences in terms of clinical outcomes and treatment regiments, as many existing targeted therapies for HER2+ cancers, such as large molecules like antibodies, have a limited ability to cross the blood–brain barrier (BBB). This evidence concerns the gene ERBB2 and cancer.